Ownership and insider activity for RenovoRx, Inc. (RNXT): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc.
Price
| Price | $1.55 |
| Market Cap | $70M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.1M | $1.8M | $15.2M | $4.4M | $1.2M | $7.2M | $7.0M |
| Short-term Investments | 0 | 0 | 0 | $2.0M | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | $43000 | $139000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | $189000 |
| Total Current Assets | $2.3M | $1.9M | $16.3M | $7.3M | $1.5M | $7.8M | $7.9M |
| Property, Plant & Equipment | 0 | 0 | $6000 | 0 | 0 | $290000 | $202000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $2.3M | $1.9M | $16.3M | $7.3M | $1.5M | $8.1M | $8.1M |
| Accounts Payable | $538000 | $162000 | $525000 | $534000 | $561000 | $586000 | $799000 |
| Short-term Debt | 0 | $2.8M | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $805000 | $4.1M | $938000 | $1.1M | $1.2M | $1.9M | $2.0M |
| Long-term Debt | 0 | $23000 | 0 | 0 | 0 | 0 | $107000 |
| Total Liabilities | $805000 | $16.6M | $938000 | $1.1M | $4.5M | $3.6M | $2.7M |
| Retained Earnings | -$11.2M | -$15.0M | -$21.3M | -$31.2M | -$41.4M | -$50.2M | -$61.4M |
| Total Equity | $1.5M | -$14.7M | $15.3M | $6.2M | -$3.0M | $4.5M | $5.4M |
| Total Debt | 0 | $2.8M | 0 | 0 | 0 | $278000 | $212000 |
| Net Debt | -$2.1M | $995000 | -$15.2M | -$6.4M | -$1.2M | -$6.9M | -$6.8M |
| Working Capital | $1.5M | -$2.2M | $15.3M | $6.2M | $291000 | $5.9M | $5.9M |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 5.74 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -8.04 |
Profitability
| Return on Equity | -145.63% |
| Return on Invested Capital | -139.74% |
| Return on Assets | -107.09% |
| Gross Margin | 84.41% |
| Operating Margin | -678.04% |
| Net Margin | -621.71% |
Related companies: ANVS · BCAB · CALC · CELU · ELUT · LTRN · MAIA
Explore sector: Healthcare · Biotechnology
More sections of RNXT: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks